



Patient Group Direction for the supply of Varenicline to named patients registered on the Public Health Services (PHS) - Smoking Cessation Service attending community pharmacies in NHS Borders.

This document authorises the supply of Varenicline by Accredited Pharmacists to named patients registered on the Public Health Services (PHS) - Smoking Cessation Service attending community pharmacies in NHS Borders who meet the criteria for inclusion under the terms of the document

The Accredited Pharmacists seeking to supply Varenicline must ensure that all patients have been screened and meet the criteria before supply takes place

The purpose of this Patient Group Direction is to allow management of Smoking Cessation in NHS Borders by Accredited Pharmacists.

This direction was first authorised on: August 2014

The direction was reviewed and updated on: November 2016

The direction will be reviewed on: November 2018

Author of PGD: Adrian MacKenzie, Lead Pharmacist, Primary and Community Care.

Clinician Responsible for Training and Review: Catriona Davies, Health Improvement Specialist - Smoking Awareness Service Co-ordinator

Specialist clinical review by: Catriona Davies, Health Improvement Specialist - Smoking Awareness Service Co-ordinator



Patient Group Direction for the supply and/or administration of varenicline without a prescription for a named individual by Accredited Pharmacists contracted by NHS Borders to provide the Public Health Services (PHS) - Smoking Cessation Service .

Indication	Clients accessing the pharmacy smoking cessation service who wishes to stop smoking.
Inclusion Criteria	<ul style="list-style-type: none"> • Dependent smoker (i.e. they smoke within 30 minutes of waking up and /or find quitting unaided difficult) identified as sufficiently motivated to quit • Clients over 18 years of age • The client agrees to receive behavioural support according to the agreed protocol
Exclusion Criteria	<ul style="list-style-type: none"> • Smokers not sufficiently motivated to quit • Client under 18 years of age • Pregnant or breastfeeding women • Sensitivity to varenicline or any of its excipients • Known severe renal disease • Not to be used in conjunction with other smoking cessation therapies. • Epilepsy • Patients taking Clozapine. • On completion of the Varenicline Risk Assessment the pharmacist is unable to supply Varenicline
Referral criteria	
Cautions	<p>Physiological changes resulting from smoking cessation, with or without treatment with varenicline, may alter the pharmacokinetics or pharmacodynamics of some medicinal products, for which dosage adjustment may be necessary (examples include theophylline, warfarin, clozapine and insulin).</p> <p>In clinical trials and post-marketing experience there have been reports of seizures in patients with or without a history of seizures, treated with varenicline. Varenicline should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold. Discuss with GP or offer NRT as alternative.</p>





	<p>A large randomised, double-blind, active and placebo-controlled study was conducted to compare the risk of serious neuropsychiatric events in patients with and without a history of psychiatric disorder treated for smoking cessation with varenicline, bupropion, nicotine replacement therapy patch (NRT) or placebo. The primary safety endpoint was a composite of neuropsychiatric adverse events that have been reported in post-marketing experience.</p> <p>The use of varenicline in patients with or without a history of psychiatric disorder was not associated with an increased risk of serious neuropsychiatric adverse events in the composite primary endpoint compared with placebo.</p> <p>Clients taking medications that may be affected when they stop smoking should be advised to tell the clinician treating them of their quit attempt.</p>
Action if patient declines	Discuss alternative products if suitable and/or offer a referral to the Specialist Smoking Cessation service for further assessment
Action if Included	Supply varenicline 500 micrograms and 1mg tablets.
Action if excluded	<p>Refer to GP or Specialist Smoking Cessation Service</p> <p>Patients who are excluded from the use of Varenicline may be suitable for smoking cessation support using NRT.</p>
Drug name	varenicline tablets
Strength and form	500 micrograms and 1mg film coated tablets
Legal status	POM Prescription only medicine
Route	Oral

Dose(s)	<p>Days 1 - 3: 500 micrograms (white tablets) once daily</p> <p>Days 4 – 7: 500 micrograms tablets twice daily</p> <p>Day 8 to the end of the treatment: 1mg (blue tablets) twice daily for 11 weeks. (Reduce to 500 micrograms twice daily if not tolerated)</p> <p>Maximum single dose 1mg Maximum daily dose 2mg</p> <p>Client should set a date to stop smoking. Client should start taking varenicline 1-2 weeks before this date.</p> <p>Tablets should be swallowed whole with plenty of water and can be taken with or without food</p> <p>Patients who cannot tolerate the adverse effects of varenicline may have the dose lowered temporarily or permanently to 500 micrograms twice daily.</p> <p>For patients with moderate renal impairment who experience adverse reactions that are not tolerable, dosing may be reduced to 1 mg once daily.</p>
Drug Interactions	No clinical meaningful drug interactions have been reported.
Side Effects	<ul style="list-style-type: none"> • Nausea • Sleep disorders/ abnormal dreams • Headache • Appetite changes • Dry mouth /taste disturbances • Drowsiness • Dizziness <p>Please refer to BNF and SPC for full list.</p>
Advice and Support	<ul style="list-style-type: none"> • Advice to clients should include specific product advice on dosage, method of administration and side effects. See Appendix 2 for treatment plan. • Provide clients with the patient information leaflet from the packaging • If client experiences any significant side effects, or changes in physical or mental health they should seek advice from a healthcare professional. <p>The following general advice should also be given:</p> <ul style="list-style-type: none"> • Follow-up and obtaining further supplies

	<ul style="list-style-type: none"> • Possible changes in the body on stopping smoking e.g. weight gain <p>At the end of treatment, discontinuation of varenicline has been associated with an increase in irritability, urge to smoke, and/or insomnia in up to 3% of patients. The pharmacist should inform the patient accordingly.</p>
Informed Consent	<p>Clients must be informed that information relating to the supply of Varenicline under a PGD needs to be passed to other health service organisations in particular their GP and the NHS Scotland to ensure proper record keeping and patient safety.</p>
Records	<ul style="list-style-type: none"> • Patient's name, address, date of birth and GP details; • Date supplied and name of the pharmacist who supplied the medication; • Reason for inclusion; • Advice given to patient; • Details of any adverse drug reaction and actions taken; • Advise GP that patient has commenced treatment with varenicline (see appendix 3 for example letter); • Severe adverse reactions should be reported to the MHRA using the 'Yellow Card' reporting system
References	<ul style="list-style-type: none"> • British Nation Formulary (BNF) • Summary of Product Characteristics (SPC) for Champix®. https://www.medicines.org.uk/emc/medicine/19045 Accessed May 2016 • National Institute for Health and Clinical Excellence. Varenicline for smoking cessation. NICE technology appraisal 123, July 2007. • Medicines and Health Product regulatory Agency (MHRA) safety alert: November 2008

**Patient Group Direction for the supply and/or administration of Varenicline by
health professionals employed by NHS Borders/GP Practice**

This Patient Group Direction is approved for use by the under-signed :

Job Title	Name	Signed	Date
Senior Doctor/Dentist for relevant clinical area	Andrew Murray		12/6/17
NHS Borders Director of Pharmacy	Alison Wilson		12/1/17
NHS Borders Senior Health Professional for Clinical Area	Adrian Mackenzie		26/1/17
NHS Borders Smoking Cessation Lead	Catriona Davies		24/1/17

PGD AUTHORISED ON 25/01/2017

Signed by ADTC CHAIRPERSON: 

Name: ALISON WILSON

NHS Borders Patient Group Direction for the Supply of Varenicline by Authorised Community Pharmacists.

Authorisation

These Patient Group Directions give authority for:

(PRINT NAME of APPROVED PHARMACIST)

To supply varenicline 500 micrograms and 1mg to clients being treated by any NHS Borders Pharmacy

Requirements for a participating pharmacist

- To have satisfactorily completed the approved training:
- To have been advised to have indemnity insurance
- To maintain clinical knowledge appropriate to their practice by attending relevant study days, courses and to make themselves aware of appropriate current literature
- To act as an approved practitioner within the terms of the Patient Group Direction and to supply accordingly
- To work in an approved pharmacy

I have received, read and fully understand NHS Border's policy on Patient Group Directions

I have received the training which approved practitioners must undertake before being authorised to supply varenicline under the relevant Patient Group Direction.

I agree to act as an approved practitioner within the terms of the Patient Group Direction and proforma and to supply accordingly.

I understand that by agreeing to act as an approved practitioner under the Patient Group Direction and Service Level Agreement I am adjusting my scope of professional practice

Pharmacist's Signature: _____ **Date:** _____

Treatment Plan

Consultations	Treatment plan
1st week- Assessment week	<p>Client should set a quit date between the next 8-14 days. Supply 14 day starter pack (11 x 500 mcg tabs with 14 X 1mg tablets)</p> <p>*Make arrangement to see client again before tablets run out i.e. between days 10- 14</p> <p>Provide health behaviour change advice for example Motivational interviewing or other supportive interventions within the Quit4Good Smoking Cessation Support Skills Pack.</p>
3rd week	<p>Client should have set a quit date. Monitor carbon monoxide level. If client is still smoking, he/she should be informed that treatment with varenicline would have to be stopped if he/she continued to smoke.</p> <p>Supply 1mg varenicline tablets if required</p> <p>Make arrangement to see client the following week.</p> <p>Provide health behaviour change advice for example Motivational interviewing or other supportive interventions within the Quit4Good Smoking Cessation Support Skills Pack.</p>
4th- 12th week	<p>Monitor carbon monoxide level and check if client has stopped smoking. If client is still smoking, treatment with varenicline should be stopped.</p> <p>If client has quit smoking supply 1mg varenicline tablets as required.</p> <p>If side effects are tolerable then continue supplying Varenicline 1mg tablets as required. If client is troubled by side effects assess whether they are tolerable or whether supply should be stopped. Here you may discuss the option to dose taper at week 10 with aim of stopping varenicline after 12 weeks of treatment. Note: A 14 day starter pack (11 x 500mcg tabs with 14 x 1mg tabs) can be supplied for the last two weeks of treatment. Ensure the patient has clear instructions to take the tablets in the starter pack in reverse order to facilitate tapered discontinuation.</p> <p>Provide health behaviour change advice for example Motivational interviewing or other supportive interventions within the Quit4Good Smoking Cessation Support Skills Pack.</p>

Varenicline Clinical Risk Assessment Form

Pharmacy Stamp

Client name:

Address:

Telephone

number:

Date of birth:

GPs name &

address:

Factor	Yes	No	Notes
Is client under 18 years of age			If 'yes' - refer to Smoking Cessation Service.
Is client pregnant or breastfeeding?			If 'yes' - refer to Smoking Cessation Service
Does client suffer from known severe renal disease?			If 'yes' - Not suitable for Varenicline - discuss NRT
Does client have a history of psychiatric illness			If 'yes' - If condition is stable, consider treatment. Patients should discontinue varenicline immediately if there is any significant change in their mental health occurs and contact a healthcare professional for re-evaluation of treatment.
Does client suffer from epilepsy?			If 'yes' - discuss with GP or offer NRT.
Is client currently on another smoking cessation therapy?			If 'yes' - If yes advise patient that they must chose which pharmacotherapy they wish to use".
Is client on Clozapine?			If 'yes' - Not suitable for varenicline - discuss NRT. Advise discussing quit attempt with Mental Health Team or refer to smoking cessation service
Is client hypersensitive to Varenicline or any of its excipients?			If 'yes' - Consider use of alternative therapies

Special circumstances and any other relevant notes:

Only make a supply if you are certain that to the best of your knowledge, it is appropriate to do so.

Action taken:

Supply:

Referral to:

Advice given:

The above information is correct to the best of my knowledge. I have been counselled on the use of Varenicline and understand the advice given to me by the pharmacist.

Client's signature:

Date

The action specified was based on the information given to me by the client, which, to the best of my knowledge, is correct

Pharmacist's signature:

Date:

**GP Notification
Patient Treatment with Varenicline**

EXAMPLE

Dear Dr

Patient's name:

Address:

DOB:

I saw the above patient at the pharmacy today and I have recommended and supplied him/her with **varenicline** tablets to help him/her give up smoking. The patient would be taking varenicline for a maximum of 12 weeks. Could you please add this medicine to the patient's medication records?

No further action would be required from you, as the patient would be receiving all supplies of varenicline from my pharmacy. Please do not hesitate to contact me should you require further information

Yours sincerely

(Signature)
(Name)